Acelyrin, Inc. is a biopharmaceutical company focused on discovering, obtaining, and rapidly advancing the development and commercialization of innovative medical therapies. The firm's most advanced experimental drug is izokibep, a potent small protein therapeutic specifically designed to block IL-17A. This compound is currently undergoing Phase 3 clinical evaluations for its use in treating Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis.
| Date | Est. | Actual | |
|---|---|---|---|
| May 14, 2025 | -$0.95 | -$0.55 | Beat |
| Mar 19, 2025 | -$0.86 | -$0.79 | Beat |
| Nov 13, 2024 | -$0.84 | -$0.49 | Beat |
| Aug 13, 2024 | -$0.66 | -$0.86 | Miss |
| May 14, 2024 | -$0.93 | -$0.36 | Beat |
| Mar 28, 2024 | -$1.00 | -$0.75 | Beat |